ATE521351T1 - Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren - Google Patents

Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren

Info

Publication number
ATE521351T1
ATE521351T1 AT05761294T AT05761294T ATE521351T1 AT E521351 T1 ATE521351 T1 AT E521351T1 AT 05761294 T AT05761294 T AT 05761294T AT 05761294 T AT05761294 T AT 05761294T AT E521351 T1 ATE521351 T1 AT E521351T1
Authority
AT
Austria
Prior art keywords
butoxyiminomethylcamptothecin
treatment
uterine tumors
uterine
tumors
Prior art date
Application number
AT05761294T
Other languages
English (en)
Inventor
Paolo Carminati
Marco Corsi
Claudio Zanna
Franco Cavalli
Luca Gianni
Cristiana Sessa
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE521351T1 publication Critical patent/ATE521351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05761294T 2004-06-11 2005-06-08 Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren ATE521351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000288A ITRM20040288A1 (it) 2004-06-11 2004-06-11 Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
PCT/IT2005/000320 WO2005120643A2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Publications (1)

Publication Number Publication Date
ATE521351T1 true ATE521351T1 (de) 2011-09-15

Family

ID=34979678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05761294T ATE521351T1 (de) 2004-06-11 2005-06-08 Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren

Country Status (23)

Country Link
US (1) US7700613B2 (de)
EP (1) EP1773451B1 (de)
JP (2) JP2008501785A (de)
KR (1) KR101221640B1 (de)
CN (2) CN1953784A (de)
AR (1) AR049220A1 (de)
AT (1) ATE521351T1 (de)
AU (1) AU2005251573B2 (de)
BR (1) BRPI0511931A (de)
CA (1) CA2565213C (de)
CY (1) CY1112032T1 (de)
DK (1) DK1773451T3 (de)
ES (1) ES2372056T3 (de)
HK (1) HK1205951A1 (de)
HR (1) HRP20110718T1 (de)
IT (1) ITRM20040288A1 (de)
MX (1) MXPA06014162A (de)
PL (1) PL1773451T3 (de)
PT (1) PT1773451E (de)
RS (1) RS52038B (de)
SI (1) SI1773451T1 (de)
TW (1) TWI351283B (de)
WO (1) WO2005120643A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017513A2 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2184882T3 (es) * 1995-06-21 2003-04-16 Sod Conseils Rech Applic Nuevos analogos de la camptotecina, procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
EP1044977B1 (de) * 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin-Derivate mit Antitumor-Wirkung
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2003043584A2 (en) * 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
WO2004103358A2 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Also Published As

Publication number Publication date
PL1773451T3 (pl) 2012-01-31
ITRM20040288A1 (it) 2004-09-11
CN1953784A (zh) 2007-04-25
HK1205951A1 (en) 2015-12-31
US7700613B2 (en) 2010-04-20
CA2565213C (en) 2012-08-07
JP2008501785A (ja) 2008-01-24
AR049220A1 (es) 2006-07-05
KR101221640B1 (ko) 2013-01-14
WO2005120643A8 (en) 2006-12-14
EP1773451B1 (de) 2011-08-24
WO2005120643A3 (en) 2006-03-30
DK1773451T3 (da) 2011-11-28
AU2005251573A1 (en) 2005-12-22
ES2372056T3 (es) 2012-01-13
TW200605891A (en) 2006-02-16
JP2014231518A (ja) 2014-12-11
KR20070030246A (ko) 2007-03-15
MXPA06014162A (es) 2007-03-07
AU2005251573B2 (en) 2010-04-15
WO2005120643A2 (en) 2005-12-22
RS52038B (sr) 2012-04-30
CY1112032T1 (el) 2015-11-04
CA2565213A1 (en) 2005-12-22
HRP20110718T1 (hr) 2011-12-31
PT1773451E (pt) 2011-11-02
EP1773451A2 (de) 2007-04-18
SI1773451T1 (sl) 2012-01-31
BRPI0511931A (pt) 2008-01-22
TWI351283B (en) 2011-11-01
US20080020030A1 (en) 2008-01-24
CN104352496A (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE549330T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602006009899D1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1773451

Country of ref document: EP